



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

08/486,069 06/07/95 ENGELHARDT

D ENZ-5 (D8) (C2)

EXAMINER

HM12/1123

RONALD C FEDUS  
ENZO DIAGNOSTICS INC  
ENZO BIOCHEM INC  
527 MADISON AVENUE (9TH FLOOR)  
NEW YORK NY 10022

MARSCHEL, A

ART UNIT

PAPER NUMBER

1655

DATE MAILED:

11/23/99

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

# Office Action Summary

Application No.  
08/486,069

Applicant(s)  
Engelhardt et al.

Examiner  
Ardin Marschel

Group Art Unit  
1655



☒ Responsive to communication(s) filed on 7/9/98, 7/24/98, 2/2/99, 3/29/99, 5/1/99, 5/7/99, 6/4/99, 6/11/99, 7/22/99, 7/30/99, 8/1/99, and 9/14/99

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 35 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

## Disposition of Claim

☒ Claim(s) 284-568 is/are pending in the application

~~Of the above, claim(s) 1-283 have been canceled.~~ ~~is/are with drawn from consideration~~

☐ Claim(s) \_\_\_\_\_ is/are allowed.

☒ Claim(s) 284-568 is/are rejected.

☐ Claim(s) \_\_\_\_\_ is/are objected to.

☐ Claims \_\_\_\_\_ are subject to restriction or election requirement.

## Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

☒ The proposed drawing correction, filed on Feb 8, 1999 is ☒ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some\* ☒ None of the CERTIFIED copies of the priority documents have been

☐ received.

☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

☐ Notice of References Cited, PTO-892

☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

— SEE OFFICE ACTION ON THE FOLLOWING PAGES —

The art unit designated for this application has changed. Applicant(s) are hereby informed that future correspondence should be directed to Art Unit 1655.

Since this application is eligible for the transitional procedure of 37 CFR 1.129(a), and the fee set forth in 37 CFR 1.17(r) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.129(a). Applicants' first submission after final, filed on 7/9/98, has been entered.

Applicants' arguments and amendments; filed 7/9/98, 7/24/98, 2/2/99, 3/29/99, 5/1/99, 5/7/99, 6/4/99, 6/11/99, 7/22/99, 7/30/99, 8/11/99, and 9/14/99; have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. They constitute the complete set presently being applied to the instant application.

If applicant desires priority under 35 U.S.C. § 120 based upon a parent application, specific reference to the parent application must be made in the instant application. It is noted that this appears as the first sentence of the specification following the title. Status of the parent application (whether patented or abandoned) should also be included. If a parent application has become a patent, the expression "Patent No." should follow the filing date of the parent application. If a parent application has become abandoned, the expression "abandoned" should follow the filing date of the parent application. It is noted that citation of serial number 06/674,352 and its status has not been included in this first paragraph even though it is in the parentage line.

Claim 367 is rejected, as discussed below, under 35 U.S.C.

112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The specific localization of modified nucleotides as given in instant claim 367 has also not been found as filed and is therefore NEW MATTER. It is noted that generic locations of modified nucleotides does not support a specific specie as claimed in claim 367 of specifically two locations never disclosed together in the instant specification.

Claims 284-568 are rejected under 35 U.S.C. § 112, first paragraph, as the disclosure is enabling only for claims limited to a scope of covalent attachment sites of the cited "Sig" moiety to bases of nucleic acids wherein said sites are either the N<sup>2</sup> of guanine, the N<sup>6</sup> of adenine, the N<sup>4</sup> of cytosine, the C<sup>6</sup> of uracil, or the N<sup>7</sup> of adenine. A thorough review of the disclosure as filed has revealed that the chemistry by which nucleic acid bases may be modified so as to attach a "Sig" moiety only is disclosed for the above four attachment sites within the scope of claims 284 etc. For example, the instant disclosure does not discuss in any way the preparation of N-1 or N-3 modified purines or N-3 or C-2 modified pyrimidines. It is noted that claims 284 etc. are already limited in that certain other, non-base, attachment sites

on purines, pyrimidines, and deazapurines are not within the scope of the claims for the at least one modified base in probes used in the claimed methods. It is also noted that certain generalized labeling methods are instantly disclosed such as the formaldehyde coupling of cytochrome C as a bridge between biotin and a nucleic acid molecule on page 58 but that such generalized labeling of a nucleic acid probe lacks both instant disclosure as well as predictability as to where the attachment site is on the probe and therefore fails to predictably form attachments as instantly claimed and thus is deemed to fail to enable the broad scope of specific base modifications of the instant claims. Ruth is herein cited as summarizing the lack of knowledge at the time of the instant filing regarding the preparation of nucleic acid hybridization probes which contain a signalling moiety. The earliest disclosure of said summary of Ruth is 2/22/83 which is the filing date of the earliest parent thereof and which is also less than a year after the filing date of the instant application. This therefore summarizes the lack of broad hybridization probe preparatory knowledge even after the instant filing date. Ruth summarizes the preparatory knowledge for signal moiety containing labeled probes in column 1, line 43, through column 3, line 45. As cited therein nucleic acid hybridization probes may be prepared either chemically or enzymatically. Enzymatic synthesis using nick translation is

discussed wherein certain base modifications have been incorporated into probes but limited in use due to several factors. One of these factors is that only certain modifications may be incorporated by enzymes. Ward et al. (P/N 4,711,955) summarize the factors that were viewed as limitations on modified nucleotides in column 6, line 36, through column 7, line 17, and thereafter discuss specific base modifications with detailed and lengthy chemical steps. Ruth at column 3, lines 26-45, also summarizes that chemical synthesis has not been disclosed in the prior art as incorporating modified or reporter group containing nucleotides. Further consideration of Ruth reveals that specific base modifications are therein disclosed such as at column 10, line 57, through column 20 which are accomplished via a lengthy series of detailed reactions including the masking and unmasking of reactive side groups to prevent unwanted modifications. Ruth and Ward et al. are deemed representative of those skilled in the art at about the time of the instant filing date of the instant disclosure. In summary, those skilled in the art at the time of filing of the instant invention viewed the preparation of signal moiety containing nucleic acid probes as lengthy and detailed procedures that were discussed as being accomplished only for certain specific base modifications. It is noted that Ruth or Ward et al. only disclose base modifications at the following sites: C-8 of purines and the C-5 of pyrimidines, N<sup>6</sup> of

adenosine, and N<sup>2</sup> of guanosine, and N<sup>4</sup> of cytosine, and C-7 of 7-deazapurines. This documents the lack of enablement of most specific base modifications without detailing lengthy preparatory procedures for those skilled in the art at the time of the instant filing date. Therefore it is deemed undue experimentation to prepare base modified nucleic acid hybridization probes wherein the site of base modifications is other than the N<sup>2</sup> of guanine, the N<sup>6</sup> of adenine, the N<sup>4</sup> of cytosine, or the C-6 of uracil within the scope of instant claims 240 etc. It is again noted that the instant claims are limited so that base modifications at the C-8 of purines, the C-5 of pyrimidines, and the C-7 of 7-deazapurines are not within their scope. Applicants have supplied several references in their submission, filed 9/14/99, regarding the enablement of non-Ward positions. These references have been reviewed and are persuasive that the N-7 position on the adenine base is defined in the art in such a way as being utilizable in such nucleobase labeling. The Zn labeling references, however, attach Zn at the site where purine bases attach to either ribose or deoxyribose and thus is not enabling for labeling hybridization probes as required in the instant disclosure.

Claims 284-328, 331, 337-372, 376-395, 402-405, 407, 408, 410, 412, 413, 415, 416, 418, 419, 421, 422, 424, 425, 427, 428, 430, 431, 433, 434, 436, 437, 439, 440, 442, 443, 445, 446, 448,

449, 451, 452, 454, 455, 457, 458, 460, 461, 463, 464, 466, 467, 469, 470, 472, 473, 475, 476, 478, 479, 481, 482, 484, 485, 487, 488, 490-495, 497, 498, 500, 501, 503, 504, 506, 507, 509-515, 517-519, 522, 523, 528, and 530-568 are rejected under 35 U.S.C. § 112, first paragraph, as the disclosure is enabling only for claims limited to "SM" moieties which are either ribose or deoxyribose. It is noted that claim 284, lines 13-15, cite "PM" attachment points but does not therein limit the "SM" moiety to the above sugar types. Thus, the scope of "SM" is only presently limited in claims 284 etc. to being a "furanose moiety" which is much broader in scope than that of ribose or deoxyribose. It is noted that there is no instant discussion as to how to practice the synthesis of nucleotides with "SM" moieties other than that of ribose or deoxyribose. It is noted that in order to broadly practice sugar moieties usage both the synthesis of "PM" attachment is required as well as the "Sig" attachment. Additionally hybridization between the nucleic acid of interest and the oligo- or polynucleotide must still be permitted. No guidance whatsoever has been instantly set forth directed to accomplishing this broad sugar moiety practice other than that directed to ribose or deoxyribose sugars which permit hybridization via specific conformations in nucleic acid polymers. It is noted additionally that the numerous examples given in the specification do not include any sugar practice



other than ribose or deoxyribose. In the above scope rejection directed to base labeling practice the need for detailed and lengthy procedures to enable the person skilled in the art to prepare nucleotide analogs as well as their incorporation into polymers is summarized. These disclosures include complex chemical protection requirements including those directed to sugar side group protection as well as considerations such as whether enzymes would recognize and incorporate nucleotides into polymers or not as well as other considerations as discussed above. Thus, it is deemed undue experimentation to practice nucleotide compound and polymers containing these compounds without such detailed and lengthy procedural guidance. In summary, such detailed and lengthy guidance is instantly set forth only for "SM" practice directed to ribose or deoxyribose and it is deemed undue experimentation to practice "SM" moieties other than ribose and deoxyribose given the limited instant disclosure.

Claims 284-375, 381-384, 396-400, and 402-568 are rejected, as discussed below, under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 284, part (b), cites the detection of the presence of "oligo- or polynucleotides which have hybridized to said nucleic

acid of interest" but is vague and indefinite when considered in view of part (a) of the claim. Said part (a) cites the practice of "hybridizing..." without any selectivity or specificity directed to preventing hybridization to nucleic acids that are not the "nucleic acid of interest". Thus, such "permitting" practice is reasonably interpreted as inclusive of all levels of stringency including conditions where hybridization is permitted to not only "nucleic acid of interest" but also to other nucleic acids that may be only 90% complementary, 70% complementary, or even only 20% complementary, etc. to the "oligo- or polynucleotide" cited in part (a). With this broad complementarity practice possible within the scope of part (a), what is meant by applicants' citation of the detecting practice of part (b)? Do applicants mean that selectivity or specificity is to be practiced at the detection step and not at the hybridization step? This suggests that the detecting step is not just a detecting step but is also inclusive of some selection practice. Such a selection practice is not given in step (b) as presently worded. It is noted that the commonly performed practice of a hybridization assay is to control the hybridization step, herein step (a) rather than step (b), so as to be selective as desired. Then the detection step is only directed to the detection of a signal which is then indicative of the presence of the "nucleic acid of interest" in the sample. This, however, is

not how claim 284 is presently worded. This unclarity causes even more concern regarding claims such as 324 or 325 which are directed to genetic disorder detection. Clarification is requested as to what applicants mean for the metes and bounds of parts (a) and (b) regarding how the presence of the "nucleic acid of interest" is indicated in the sample versus nucleic acids that are not of interest and what signal is determinative of said presence. Do applicants mean to include some selectivity in either of parts (a) or (b) and, if so, which part or parts? This unclarity is present in all of the instantly depending claims due to their direct or indirect dependence from any of the instant independent claims as listed in the above rejected claims hereinunder.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 396 and 397 are rejected under 35 U.S.C. § 102(b) as being anticipated by Kourilsky et al. (GB 2,019,408).

Kourilsky et al. prepares hybridization probes made up of polynucleotides which are labeled with cytochrome C and biotin as given on page 1, line 25, through page 2, line 52, which are then

utilized in hybridization assays. The instant claims rejected as listed above include any labeling location and thus are anticipated by the reference.

No claim is allowed.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (See 37 CFR § 1.6(d)). The CM1 Fax Center number is either (703) 305-3014 or (703) 308-4242.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ardin Marschel, Ph.D., whose telephone number is (703) 308-3894. The examiner can normally be reached on Monday-Friday from 8 A.M. to 4 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703) 308-1152.

Any inquiry of a general nature or relating to the status of this application should be directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196.

November 19, 1999

*Ardin H. Marschel*  
ARDIN H. MARSCHEL  
PRIMARY EXAMINER